top of page

Cosmetic or Medical Device? Which Regulatory Route Your Baby Eczema Product Should Take in the EU and US

Oct 8
10 min read

Baby eczema product classification turns on 1 question the formula cannot answer: what the product claims to do. The same cream can be a cosmetic under Regulation (EC) No 1223/2009. It can also be a medicinal product under Directive 2001/83/EC or a Class I medical device under Regulation (EU) 2017/745. In the US, a claim to relieve eczema moves the product into the drug lane. Set the route after the claim.

DEVA Skincare has made baby and sensitive skin products for 20 years. The company runs 4 sites with 20 million units of monthly capacity. We open every project with the market and the claim, because the route decides the brief, the file and the test list.

Three unbranded baby cream containers with ivory cream lift marks on a grey surface

Which Three Routes Can a Baby Eczema Product Take?

Three routes exist in the EU and 2 in the US, and the intended purpose picks one. Nothing in the ingredient list decides it. Petrolatum in a cosmetic stays a cosmetic. A baby eczema product classification reads from the label outward, not from the bench outward.

Route

Legal instrument

Claim it supports

Who assesses it

Cosmetic

Regulation (EC) No 1223/2009 in the EU; FD&C Act section 201(i) with MoCRA in the US

Soothes, moisturizes and protects

No pre-market approval; a safety file plus a notification

Medicinal product or OTC drug

Directive 2001/83/EC in the EU; FD&C Act section 201(g)(1) with 21 CFR Part 347 in the US

Treats, prevents or relieves eczema

A marketing authorization in the EU; monograph conformance in the US

Medical device

Regulation (EU) 2017/745 in the EU; FD&C Act section 201(h) in the US

Manages a skin condition through a physical barrier

A notified body for most classes in the EU; FDA device controls in the US

 

The borders do not line up between the 2 markets. The EU keeps 3 legal categories and asks which one the product belongs to. The US keeps 2 practical lanes and adds a narrow device door.

What Makes a Baby Eczema Product Classification Shift to a Drug?

In the US, 1 word moves a baby eczema product classification into the drug lane: eczema. FDA states on its own cosmetics pages that treatments for skin conditions such as eczema are drugs. FD&C Act section 201(g)(1) covers articles intended to treat, mitigate, cure or prevent disease.

A moisturizer that only improves the look of skin stays a cosmetic and follows MoCRA. A product that promises relief from eczema is a drug, whether or not it also moisturizes. Many baby products fall inside both categories, and a baby eczema product classification that lands in both must meet both sets of rules.

Which Actives Can Carry the US Eczema Claim?

Colloidal oatmeal is the only botanical in the OTC skin protectant monograph at 21 CFR 347.10(f), at a minimum of 0.007 percent, or 0.003 percent with mineral oil. That floor is low, so a formula clears it without a heavy load.

The monograph also fixes the label sentence: temporarily protects and helps relieve minor skin irritation and itching due to rashes, eczema, poison ivy, oak or sumac, and insect bites. A product inside the monograph needs a Drug Facts panel and no pre-market approval. Any claim outside that sentence leaves the monograph and points to a new drug application.

The device door exists but stays narrow. FD&C Act section 201(h) defines a device as an article that does not achieve its main purpose through chemical action and is not metabolized. Eczema creams are not in the FDA wound dressing groups at 21 CFR 878.4018 and 878.4020. A US product that promises eczema relief lands in the drug lane.

When Does EU Law Treat a Baby Eczema Cream as a Medicinal Product?

In the EU, 2 instruments decide whether a baby eczema cream is a medicine, and both read the presentation rather than the chemistry. Directive 2001/83/EC Article 1(2) defines a medicinal product by function and by presentation. A product presented as having properties for treating or preventing disease is a medicinal product on that ground alone.

Article 2(2) of the same directive settles the tie. Where a product falls inside both definitions, the medicinal rules apply. Regulation (EC) No 1223/2009 Article 2(1)(a) also excludes any product with a pharmacological, immunological or metabolic action from the cosmetic category. Eczema is a disease. An EU cosmetic may soothe and protect. It may not claim to treat, and a baby eczema product classification that reaches for that word leaves the cosmetic lane.

Staying cosmetic still carries duties. Article 4 requires a Responsible Person in the EU. Article 10 and Annex I require a product information file with a safety report, and Article 13 requires a CPNP notification before market entry. Every claim must also pass the common criteria in Regulation (EU) No 655/2013: legal compliance, truthfulness, evidential support, honesty, fairness and an informed decision.

When Can a Baby Eczema Cream Be a Medical Device in the EU?

In the EU, 1 regulation governs the device route, and it opens only when the product works by physical means. Regulation (EU) 2017/745 Article 2(1) covers products intended to prevent, monitor, treat or alleviate disease, so long as the main action is not pharmacological, immunological or metabolic. A barrier cream passes that test. A cream built on an anti-inflammatory active does not.

Annex VIII section 2.8 defines injured skin as skin that shows a pathological change or a change following disease. Eczema skin meets that definition, so a baby eczema product classification on the device route starts at Rule 4 of Annex VIII.

What the cream does on injured skin

Class under Annex VIII Rule 4

Acts as a mechanical barrier, gives compression or absorbs exudate

Class I

Manages the microenvironment of the injured skin

Class IIa

Sits mainly on a dermis breach that heals by secondary intent

Class IIb

 

MDCG 2021-24 Rev.1, published on 20 April 2026, is the current classification guidance under the MDR. It replaced the October 2021 text and updated the tables for Rules 2, 8, 10, 12, 16 and 22. Classification follows the intended purpose the manufacturer writes down, and where several rules apply the strictest one wins. A baby eczema product classification should also expect uneven answers, because the cosmetic, medicine and device borders are not harmonized across member states. The Commission Manual on Borderline and Classification under Regulations (EU) 2017/745 and (EU) 2017/746, Version 5, published in April 2026, is the reference for those cases.

The device route carries a heavier administrative load. Since 28 May 2026, actor registration and device registration in EUDAMED are mandatory, after Commission Decision (EU) 2025/2371 was published on 27 November 2025. Devices already on the market need registration by 28 November 2026. A Class I device can self-declare, but it still needs a quality system, a clinical evaluation and an EU authorized representative.

Where Does the Cosmetic Claim Line Sit in a Baby Eczema Product Classification?

Claim wording decides the route, and 1 line of label copy can separate a cosmetic from a drug. In a baby eczema product classification, the wording has to match the file behind it.

Market

Route

Wording that holds the route

Wording that moves the product out

EU

Cosmetic

Soothes, moisturizes, protects, keeps skin comfortable

Treats, prevents or relieves eczema

EU

Medicinal product or medical device

Relieves the symptoms of eczema; forms a protective barrier

A claim with no evidence behind it

US

Cosmetic

Moisturizes and softens dry skin; improves the look of dry patches

Relieves eczema; treats a rash

US

OTC drug under 21 CFR Part 347

The fixed monograph sentence that names eczema and rashes

Cures eczema; rebuilds the barrier; prevents flares

 

Two details get missed. The US monograph sentence is fixed, so the words cannot be rephrased for brand voice. In the EU, an unsubstantiated claim fails the common criteria even when the product is legally a cosmetic, and the safety report has to cover the claim as written.

What Does Each Route Ask You to File?

Each route asks for a different file, and the device route is the heaviest of the 3. A baby eczema product classification that lands on the wrong row pays for it in time.

Route

What you file

Who assesses it

When it starts to run

EU cosmetic

Product information file with a safety report, CPNP notification, a named Responsible Person

The Responsible Person, with no pre-market approval

Before the first unit reaches the market

EU medicinal product

A marketing authorization dossier

The competent authority or the European Medicines Agency

Before any supply, and usually years ahead

EU medical device

Technical documentation, a quality system, a clinical evaluation, a CE mark, EUDAMED registration

A notified body for Class IIa and above; self-declaration for most Class I

New devices before placement; existing devices by 28 November 2026

US cosmetic

MoCRA facility registration, product listing, safety substantiation, adverse event records

FDA, with no pre-market approval

Registration renewed every 2 years, listing updated every year

US OTC drug

Drug establishment registration, drug listing, a Drug Facts panel, monograph conformance

FDA, with no pre-market approval for a monograph product

Before interstate commerce

 

The MoCRA dates are concrete. FDA began enforcing facility registration and product listing on 1 July 2024, after a 6 month delay from the statutory date. Serious adverse events go to FDA within 15 business days. Small businesses below an average of 1 million US dollars in yearly US cosmetic sales are exempt.

MoCRA registration is not approval, and it does not cover drugs. A product that carries a drug claim follows drug rules instead: drug establishment registration, drug listing and a Drug Facts panel. A product under both definitions has to satisfy both.

Which Route Should a Brand Choose First?

A cosmetic baby eczema product classification reaches the market in 2 filings in each region. It needs a safety file and a notification in the EU, and registration plus listing in the US.

The trade-off follows the promise. Comfort claims keep the product in the lighter lane and limit the marketing copy. A relief claim opens the pharmacy shelf, and it costs the heavier file. A barrier claim with a stated medical purpose opens the device route in the EU, which is lighter than the medicines route.

Neither region runs a separate children's product category, so the age of the user does not change the route. It changes the evidence inside the route, because a baby product has to justify a safety margin for a group that cannot report a reaction.

For a 2 market launch, design 1 base formulation that can carry 2 claim sets. Keep the actives and the vehicle identical, and separate the 2 products by label and by the file behind them. That keeps 1 baby eczema product classification from forcing 2 development programs.

What Evidence Does Each Route Need Before Release?

A claim needs evidence, and a baby eczema product classification sets 3 evidence standards, one per route. A cosmetic claim needs support under the common criteria plus a safety report. A drug claim needs the level the monograph or the authorization expects. A device claim needs a clinical evaluation against the intended purpose.

Test

What it supports

Window

Preservative challenge test

A preserved water-based cream holding an oat dispersion

4 weeks

Cell efficacy and toxicity panel

Tolerance of each active at its use level

4 weeks

Chorioallantoic membrane irritation assay

Irritation potential on a vascular membrane

4 weeks

Multi-active compatibility

Stability of the actives together in 1 base

4 weeks

TEWL and texture imaging

Barrier support behind a comfort claim

4 weeks

28 day human use test

The claim as written, on adult panels

4 weeks

 

The protocols run in parallel, so the full matrix does not add 4 weeks 6 times over. Sampling takes about 1 week from a confirmed brief. Mass production starts about 6 weeks after sample approval. Each batch also clears 72 inspection and process control steps at any order size.

One limit deserves a plain statement. You cannot run a controlled patch test or a use test on infants. Prove the claim in vitro, then on adult panels, then support it with the published record.

What Does DEVA Skincare Bring to a Baby Eczema Product?

DEVA Skincare has made baby and sensitive skin products for 20 years and holds 70+ granted patents. Our baby eczema programs run in a 100,000 grade GMPC cleanroom, with laboratory work built to CNAS standards. The R&D group carries 5,000+ mature formulas, 30+ engineers and 6 university partnerships.

Two platforms matter here. Ultrasonic microfluidic homogenization controls particle size in the oil phase, which decides how a barrier film forms. Nano-liposome encapsulation carries poorly soluble actives deeper into a damaged barrier.

Evidence capacity answers the second half. The laboratory holds 150 efficacy and safety protocols. Two baby care lines we manufacture each ship about 13 million units a year.

Every quote follows our published terms. Standard MOQ is 5,000 units per SKU for emulsion and wash formats. Aluminium cans start at 10,000 units. Sampling takes 1 week. Mass production starts 6 weeks after sample approval. Each test protocol runs about 4 weeks.

Send us the target market, the claim as written and the pack format through the inquiry form on this page. We will place your baby eczema product classification on the right route, name the file and the tests that route asks for and quote against your actual pack. If you already hold a claim set and want a second read, send that too.


Can a baby eczema cream be sold as a cosmetic in the EU?

Yes, if the claims stay on soothing, moisturizing and protection. A cosmetic may not claim to treat, prevent or relieve eczema, because eczema counts as a disease under Directive 2001/83/EC. Keep the copy on comfort and barrier support, and back every claim with evidence under Regulation (EU) No 655/2013.

Yes, in most cases. FDA lists treatments for skin conditions such as eczema as drugs, and a skin protectant such as colloidal oatmeal at 0.007 percent or more carries the monograph claim. A moisturizer that only improves appearance stays a cosmetic. The claim, not the texture, decides the category.

Only if the product claims a medical purpose and works by physical means. A barrier cream for injured skin can be a Class I device under Annex VIII Rule 4, or Class IIa when it manages the skin microenvironment. A cosmetic that makes no medical claim needs no device file at all.

The cosmetic route is the fastest in both markets. It needs a safety assessment, a product information file and a CPNP notification in the EU, and MoCRA facility registration plus product listing in the US. No pre-market approval applies. A drug or device claim adds months and a much larger file.

No. MoCRA registration and listing attach to cosmetic products. A product that carries a drug claim follows the drug rules instead, including drug establishment registration, drug listing and a Drug Facts panel. A product that falls under both definitions has to meet both sets of duties.

Send the target market, the claim wording and the pack format through the inquiry form on this page. A baby eczema product classification follows the intended purpose, so we read the claim first, name the matching route and list the file and the tests each market asks for.


Comments


bottom of page